Genomic characterization of an esthesioneuroblastoma with spinal metastases: illustrative case Authors: Bianca M Marin, Nathan K Leclair, Erica Shen, Avery Buehler, Upendra P Hegde, Qian Wu, Kevin Becker, Lei Li, Seth Brown, Leo J Wolansky, Hilary Onyiuke, David Choi, Ketan R Bulsara Published: 2023 ABSTRACT AbstractBACKGROUNDEsthesioneuroblastoma (ENB) is a rare neoplasm of the sinonasal tract. Currently, the optimal treatment includes maximal resection combined with radiotherapy and/or chemotherapy. Although ENBs often recur and have an aggressive clinical course, spinal metastases are extremely rare and the underlying molecular mechanisms are poorly understood.OBSERVATIONSHere, the authors describe a 50-year-old male with an aggressive ENB, initially treated with resection and chemotherapy/radiation, who developed multiple thoracic and lumbar spinal metastases. The authors performed targeted exome sequencing on both the resected primary tumor and biopsied spinal metastases, which revealed 12 total variants of unknown clinical significance in genes associated with the PI3K/AKT/mTOR pathway, chromatin remodeling, DNA repair, and cell proliferation. Six of these variants were restricted to the metastatic lesion and included missense mutations with predicted functional effects in GRM3, DNMT3B, PLCG2, and SPEN.LESSONSThis report discusses the potential impact of these variants on tumor progression and metastasis, as well as the implications for identifying potential new biomarkers and therapies.Keywords: esthesioneuroblastoma, spinal metastasis, genomicsABBREVIATIONS: CNS = central nervous system; CT = computed tomography; EMT = epithelial-mesenchymal transition; ENB = esthesioneuroblastoma; MRI = magnetic resonance imaging; PET = positron emission tomography; VIP = cisplatin, etoposide, and ifosfamide; VUS = variant of unknown clinical significance Esthesioneuroblastoma (ENB), also known as “olfactory neuroblastoma,” is a rare neoplasm of the sinonasal tract. It originates from olfactory neuroepithelium in the nasal cavity or cribriform plate1 and accounts for only for 3%–6% of sinonasal tract neoplasms.2 While ENB can occur at any stage of life, it has a bimodal distribution with a mean age at presentation between 33 and 65 years.3 As the ENB grows, it causes obstruction of the nasal cavity, resulting in frequent epistaxis, anosmia, sinusitis, and facial pain.4 The rare incidence of these tumors has made it difficult to standardize treatment modalities and discover new therapeutic strategies. Currently, the optimal treatment is maximal resection, followed by radiotherapy for low-grade tumors with additional chemotherapy for high-grade, recurrent, or metastatic tumors.5 The outcomes with this standardized treatment remain dismal. While there is no standard chemotherapy regimen for ENB, commonly used agents include cisplatin and etoposide or doxorubicin, or vincristine and an alkylating agent.6 Targeted therapies are not often used due to a lack of efficacy data, although there are a few reports of stable disease after treatment with sunitinib,7 sunitinib and cetuximab,8 imatinib,9 bevacizumab,10 and everolimus.11 Despite treatment, ENBs frequently recur and have an aggressive clinical course. Recurrence is local in approximately 60% of cases, whereas 10%–30% of tumors will metastasize.12 Recurrence can happen any time after the completion of treatment, even more than 10 years later.13 The Kadish classification, which is used to clinically stage ENBs, estimates upwards of 90% overall survival when the lesion is localized to the nasal cavity but less than 45% overall survival if the tumor extends beyond the nasal and paranasal sinuses.14 ENBs most commonly spread to the cervical lymph nodes, but distant metastasis to the central nervous system (CNS), parotid glands, breast, lungs, abdominal viscera, pelvis, and long bones can also develop.15 Spinal cord metastases from ENB are particularly rare, with fewer than 40 cases reported so far. Given the poor prognosis of metastatic ENB, better treatment options are needed. A molecular understanding of the genomic influences on ENB progression may elucidate new targets and biomarkers. Limited case studies have described the importance of genomic information in tailoring targeted therapies,8,16 and other studies have examined the prognostic value of cytogenetic and mutation-level alterations in high-grade, metastatic ENBs.17,18 However, there are few data comparing metastatic versus primary lesions in individual patients, which carries value in understanding tumor evolution from the standpoint of therapeutic targets and the identification of biomarkers that may predict metastasis. Here, we present the case of a rapidly progressing ENB that developed multiple spinal metastases within 1 year of initial presentation. To identify potential targets for therapeutic interventions, we performed exome sequencing of a panel of 500 cancer-associated genes on the resected primary tumor and biopsied metastatic tumor samples. This gave us the opportunity to perform the first paired genomic characterization of an ENB with distant spinal metastases and to shed light on the potential mutational processes associated with therapy resistance and tumor progression. Illustrative Case Clinical Presentation and Neuroimaging A 50-year-old male presented to the emergency department with complaints of left facial pain and periorbital swelling, secondary to recent trauma. Labs obtained at the time were remarkable for an elevated white blood cell count of 13,300/µL, and he began empirical treatment with vancomycin and ampicillin/sulbactam for suspected infection. Head computed tomography (CT) demonstrated a left buccal space abscess, which was subsequently drained. Follow-up nasal endoscopy demonstrated a prominent polypoid soft tissue mass filling the left nasal cavity. Magnetic resonance imaging (MRI) of the face and orbit revealed a poorly enhancing, 44 × 28 × 12–mm soft tissue mass in the left nasal cavity that obstructed outflow from the left maxillary, ethmoid, and frontal sinuses (Fig. 1). Biopsy of the mass suggested a neuroblastoma diagnosis. Clinical course and radiological characterization of primary and metastatic esthesioneuroblastoma (ENB). The patient’s clinical timeline in months is indicated with relevant clinical events, surgical interventions, medical therapy, and representative radiology images indicated as dots, to denote specific points in time, and boxes, indicating the duration of treatment. Initial magnetic resonance imaging (MRI) revealed a contrast-enhancing soft tissue mass in the left nasal cavity with extension into the paranasal sinuses, which poorly enhanced with contrast. A heterogeneously enhancing area suggestive of recurrent tumor was present in the MRI obtained 2 months after resection and correlated with areas of avid fluorodeoxyglucose (FDG) uptake on positron emission tomography–computed tomography (PET-CT) but responded to treatment with cisplatin, etoposide, and ifosfamide (VIP). Eleven months after the initial presentation, extensive intracranial and spinal metastases were noted. Enlarged images of spinal MRI sequences demonstrated extensive tumor burden at dissemination. FLAIR = fluid-attenuated inversion recovery; RT = radiation therapy; T1 C+ = T1-weighted MRI with intravenous contrast; LLE = left lower extremity. Surgical Treatment An endonasal approach was used to remove the tumor from the nasal cavity and the maxillary, sphenoid, and ethmoid sinuses, as well as the periorbita and cribriform plate. A bifrontal craniotomy was performed to resect residual tumor invading the anterior skull base and the dura. The resulting dural defect was repaired with a watertight suture and reinforced with dural matrix. A split calvarial bone graft was used to repair the anterior skull base defect. A vascularized pericranial flap was used to reconstruct the anterior skull base, and an abdominal fat graft harvested from the upper right quadrant was placed over it to complete the reconstruction. Margins were assessed at the time of surgery and determined to be negative. Pathology Histopathology of the resected primary mass was compatible with a diagnosis of olfactory neuroblastoma (Fig. 2). The tumor presented a nesting pattern with rare clusters of cells forming Homer Wright rosettes, but with a high proliferation index (MIB1 staining at 70%) and areas of necrosis suggestive of a high-grade tumor (Hyams grade IV; Fig. 2). Staining was positive for synaptophysin, chromogranin A, and neuron-specific enolase (NSE). Stains for AE1/AE3 showed aberrant expression of keratin, and PD-L1 and glial fibrillary acidic protein (GFAP) staining were negative (Fig. 2B). Histopathological characterization of the resected primary tumor. A: Hematoxylin-and-eosin staining of the tumor sections were imaged at variable magnifications. At an original magnification ×20, a nesting pattern with rare clusters of cells forming Homer Wright rosettes (black arrowheads) can be seen. B: Immunohistochemistry staining demonstrated tumor positivity for synaptophysin, chromogranin A, and neuron-specific enolase (NSE). Stains for AE1/AE3 showed aberrant expression of keratin. The MIB1 proliferation index was estimated at 70%. Glial fibrillary acidic protein (GFAP) staining was negative. Original magnification ×20. Postoperative Course The patient was transiently lost to follow-up. When he did return, approximately 2 months after surgery, MRI demonstrated significant tumor burden and positron emission tomography (PET)-CT showed a fluorodeoxyglucose (FDG)-avid, 64 × 53 × 43–mm mass in the nasal/paranasal sinus region (Fig. 1). Given concerns for recurrent disease, the patient elected to undergo a combined regimen of radiation and chemotherapy with cisplatin, etoposide, and ifosfamide (VIP regimen). Follow-up MRI and PET-CT demonstrated positive disease response after two VIP cycles (Fig. 1). After four cycles of VIP, the patient began radiation therapy with concurrent carboplatin chemotherapy. He received 10 cycles of radiotherapy to the nasal cavity, paranasal sinus, and neck region bilaterally. Carboplatin was held after four cycles due to development of thrombocytopenia. Metastatic Disease Approximately 1 month and a half after completing radiotherapy, the patient presented with left lower-extremity pain and weakness as well as urinary retention. Neurological examination of the lower extremities revealed decreased strength and sensation bilaterally. MRI revealed multiple intramedullary lesions along the thoracic spine as well as multiple intradural lesions along the lumbar spine (Fig. 1). Biopsy of one of the spinal lesions was consistent with metastatic disease, having a similar staining profile as the primary tumor (Fig. 3). Given the diffuse nature of the lesions, the patient received only palliative radiation and died shortly after, 1 year from the initial diagnosis. Histopathology of a spinal metastasis. Immunohistochemistry staining of a biopsied spinal metastasis demonstrated a similar staining pattern as the primary lesion with a high MIB1 index and positivity for NSE, chromogranin A, synaptophysin, and AE1/AE3. Original magnification ×20. Genomics Targeted exome sequencing of a panel of 500 cancer-associated genes (Jackson Labs ActionSeq) was performed on both the resected primary tumor and the biopsied metastatic sample. Microsatellite instability was negative in both samples. Sequencing revealed 12 total variants of unknown clinical significance (VUSs) across the two samples (Fig. 4). No germline testing was performed. Genomic variants uncovered in the primary tumor and spinal metastasis. Primary and metastatic tumor tissue samples underwent targeted genomic sequencing and revealed 12 total variants of unknown clinical significance (VUSs) (ASCO/AMP/CAP Tier III): 4 uncovered in both primary and metastatic samples, 2 restricted to the primary tumor, and 6 restricted to the metastatic tumor. Genomic variant and effect on protein amino acid sequence are listed. Variant effect prediction classified by PROVEAN, SIFT, and PolyPhen-2. Patient Informed Consent The necessary patient informed consent was obtained in this study. Discussion Esthesioneuroblastoma is a rare and aggressive cancer of the olfactory epithelium.1 Tumor recurrence and progression frequently happen on current treatment strategies, including surgery and adjuvant chemotherapy/radiation.5 Recent studies have used next-generation sequencing techniques to understand what drives ENB tumorigenesis and uncover novel targets. Overall, TP53 was found to be the most commonly mutated gene in primary ENB, with multiple alterations in other genes associated with the PI3K/AKT/mTOR pathway, chromatin remodeling, transcriptional regulation, DNA repair, and cell survival, proliferation, and adhesion/migration.17,19–22 However, there is limited information on whether these alterations are maintained in metastatic tumors and which additional mutations can promote disseminated CNS disease. While 10%–30% of ENBs metastasize, only three reports have included metastatic samples.8,19,23 Here, we present a paired genomic characterization of a primary ENB with spinal metastases to the thoracic and lumbar spine (Fig. 4). Targeted exome sequencing revealed a total of 12 VUSs across the primary and metastatic tumors. Our patient did not have any mutations in the TP53 gene, but we did find multiple VUSs in genes associated with the PI3K/AKT/mTOR signaling pathway. This pathway, which regulates cell proliferation and survival,24 is altered in 25% of primary ENBs21 and 27% of recurrent ENBs.17 The pathway can be activated through the IGF1R receptor tyrosine kinase and its IRS-1 adaptor protein,25 both of which were mutated in our patient (Fig. 4). The IGF1R gene has been implicated in angiogenesis, epithelial-mesenchymal transition (EMT), and metastasis of multiple cancer types, including neuroblastoma.26 Similarly, IRS-1 was shown to promote EMT and lead to the development of metastases in head and neck squamous cell carcinoma tumors.27 The IGFR1R variant was present in both the primary and metastatic samples. However, since germline testing was not performed for this patient, it is unclear whether this variant was present in the germline, potentially contributing to the tumor development and dissemination, or if it simply arose early in the tumor evolution. In contrast, the IRS1 VUS was unique to the metastatic tumor and highly abundant (variant allele frequency of 95.8%), suggesting that this mutation was acquired later as the cells proliferated and adapted to their new environment. Future functional studies are needed to test this hypothesis, as well as the potential for the IGF1R variant and other PI3K/AKT/mTOR–associated mutations to serve as biomarkers for ENB progression and metastasis. In non–small cell lung cancer, IGFR1R has been shown to promote metastasis initiation and progression and is currently investigated as a potential biomarker for predicting clinical evolution and treatment response.28 Four of the six VUSs identified in the primary tumor were maintained in the metastatic tumor, which supports their clonal relationship. One common variant was in the gene for SMARCA4, a catalytic subunit of the SWI/SNF chromatin remodeling complex.29 SMARCA4 is frequently mutated in aggressive cancers carrying poor prognoses, and multiple variants for this gene have been previously reported in ENBs (p.G1232S, pI1318T, p.V1593I).17,20,30 However, this is the first report of the SMARCA4 p.D1314N variant detected in our patient. PROVEAN (Protein Variation Effect Analyzer)31 and SIFT (Scale-Invariant Feature Transform)32 computational algorithms used to predict the impact on protein function both suggested that this variant is likely deleterious (Fig. 4). SMARCA4-deficient ovarian carcinomas and non–small cell lung tumors are susceptible to CDK4/6 inhibitors, such as palbociclib, abemaciclib, and ribociclib; therefore, these targeted therapies can potentially be extended to SMARCA4-mutant ENBs.33,34 The primary and metastatic tumors also shared a variant in the AR gene that encodes the androgen receptor. Recent studies have implicated the androgen receptor in the development and progression of pediatric neuroblastomas and have shown therapeutic effects for androgen antagonists in vitro and in vivo.35,36 However, it is unknown whether this could also apply to ENBs, which appear to have a more heterogeneous androgen receptor expression.37 The primary tumor also contained two unique VUSs in the FGFR1 and MLH3 genes. FGFR1 is a cell-surface receptor tyrosine kinase that regulates cell development, proliferation, and migration.38 While FGFR1 amplification has been previously identified in ENB,19 this is the first ENB report for the p.M487I variant, which has only been reported in a pediatric Wills tumor.39 MLH3 is a member of the DNA mismatch repair pathway, and the p.V595I variant identified in our patient is the first reported MLH3 variant in an ENB tumor. Both VUSs may have been present in sensitive tumor subclones that were eradicated with treatment, which may explain their absence from the metastatic tumor. The metastatic tumor also contained five additional VUSs not detected in the primary tumor. Some of these variants may reflect the emergence of resistant clones under the selective pressure of treatment and could therefore offer insight into potential mechanisms of acquired resistance. Two variants of particular interest were in the DNMT3B and PLCG2 genes. Both genes have been previously implicated in cisplatin resistance, which the patient received as part of the VIP regimen. The DNMT3B gene codes for a methyltransferase that catalyzes de novo DNA methylation.40 While the DNMT3A paralogue appears to be frequently mutated in ENBs, only one other DNTM3B variant has been reported so far (p.R42H).20 In a murine neuroblastoma model, expression of DNMT3B correlated with cisplatin drug resistance, and knockout of the gene restored sensitivity to therapy.41 Similarly, PLCG2, which codes for phospholipase C that mediates intracellular Ca2+ signaling, has been implicated in cisplatin resistance in head and neck cancers.42 The p.E783K uncovered in this patient was predicted to be deleterious to gene function by all three predictive algorithms used here (Fig. 4).31,32,43 Future functional studies should be aimed at determining the impact of these variants on the cisplatin response in ENBs and investigate their potential to serve as biomarkers for acquired resistance. Identifying unique mutations may also offer opportunities for the development of metastatic-specific therapies. One example is the p.R59Q VUS we identified in the GRM3 glutamate receptor gene. The variant has been previously reported in patients with cutaneous melanoma, and a recent study found that melanoma tumors with GRM3 mutations are more sensitive to MEK inhibitors like selumetinib.44 While functional studies are needed to determine the exact impact of the variant on the protein structure and function, the finding supports the utility of obtaining biopsies and sequencing data from metastatic lesions to identify potential targets that are absent from the primary tumor. The presented case focuses on the genomic landscape of a paired primary and metastatic ENB in a single patient. However, it is essential to mention the role of other molecular mechanisms that contribute to ENB tumorigenesis. Indeed, some groups have proposed molecular stratification schemes for ENB based on epigenetic, transcriptomic, and proteomic signatures that correlate with patient prognosis.20,21 Through these efforts, multiple subgroups of ENB have been identified, including those harboring IDH2 mutations reminiscent of gliomas and carrying a worse prognosis.20,45 Additional studies are needed to integrate these molecular phenotypes further and apply them to clinical grading. Observations Here, we present the case of a rapidly progressing ENB that developed multiple spinal metastases within 1 year of initial presentation. To identify potential targets for therapeutic interventions and mutational processes associated with resistance and progression, we performed targeted exome sequencing on the resected primary tumor and biopsied metastatic tumor samples. This is the first paired genomic characterization of an ENB with distant spinal metastases. Lessons Metastatic ENBs are rare and aggressive tumors that carry high morbidity and mortality despite conventional surgery and chemotherapy/radiation treatment. Here, we performed molecular profiling comparing a primary ENB with its distant spinal metastasis, which revealed genomic variants in crucial cancer pathways. In addition to maintaining most of the mutations found in the primary tumor, the metastasis acquired additional genomic alterations in response to its new environment and/or therapeutic pressure. While the present study offers novel and valuable insight into the genetic landscape of metastatic ENB, the findings should be interpreted cautiously, given the sample size (n = 1). ENBs can be histologically and genetically heterogeneous, and some of the identified variants may not be reflective of, or relevant to, the general patient population. Additionally, the fact that their functional significance is currently unknown adds another layer of difficulty and uncertainty. Therefore, rather than generalizing them, the results should be interpreted alongside findings from other genomic studies. For example, our findings align with previous research identifying the PI3K/AKT/mTOR signaling and SWI/SNF chromatin remodeling pathways as potential drivers for ENB initiation. Unfortunately, the availability of patient data is greatly restricted by the rarity of this tumor type, and there is still much to be discovered about the genetic makeup of ENBs, especially recurrent and metastatic ones. Overall, the present study adds to the groundwork for future analyses and the clinical utility of obtaining genomic information from patients presenting with ENBs. Identifying biomarkers in the primary tumor that predict its metastatic potential would allow us to identify patients at risk for disease progression. Similarly, detecting biomarkers of acquired treatment resistance in the metastatic tumors could help identify patients who are unlikely to respond to additional rounds of chemotherapy and necessitate the use of more personalized treatment strategies. Author Contributions Conception and design: Bulsara, Leclair, Shen, Buehler, Hegde, Becker, Brown, Wolansky, Onyiuke, Choi. Acquisition of data: Bulsara, Hegde, Wu, Becker, Li, Wolansky, Onyiuke, Choi. Analysis and interpretation of data: Bulsara, Marin, Leclair, Shen, Wu, Li, Brown, Wolansky, Onyiuke. Drafting of the article: Marin, Leclair, Shen, Buehler, Wolansky. Critically revising the article: Bulsara, Leclair, Shen, Buehler, Hegde, Wu, Wolansky. Reviewed submitted version of the manuscript: Bulsara, Marin, Leclair, Shen, Buehler, Hegde, Becker, Brown, Wolansky, Choi. Approved the final version of the manuscript on behalf of all authors: Bulsara. Statistical analysis: Leclair. Administrative/technical/material support: Bulsara, Wolansky. Study supervision: Hegde, Li, Brown, Wolansky. Supplemental Information Previous Presentations Presented virtually at the Brown University Student Neurosurgery Conference, January 15, 2022. References